(Extended Data Fig. 2 ) are often likely to be functionally heterozygous for S1PR2. Using a mixed BM chimera system in mice 3 , S1pr2 heterozygous B cells showed marked expansion in the GC relative to the follicular compartment in mesenteric lymph nodes (mLNs) and Peyer's patches (PPs) of unimmunized mice ( Fig. 1e and Extended Data Fig. 3a, b) . Overexpression of WT S1PR2 repressed the outgrowth of S1pr2 +/-GC B cells and this was also seen for mutant R329C, whereas the R147C mutation caused the receptor to lose GC growth suppressive activity ( Fig. 1 f and Extended Data Fig. 3c, d ). Based on molecular simulation analysis (Supplementary Text and Extended Data Fig. 3e-g ) we propose that the R147C S1PR2 mutant cannot attain the active conformation necessary for G-protein recruitment and signaling.
Gα12 and Gα13 often function redundantly in transmitting GPCR signals 8 . Transcripts for both G-proteins are upregulated in GC B cells, with Gna13 transcripts appearing more abundant (Extended Data Fig. 4a ). In accord with recent whole exome sequencing studies that reported mutations in GNA13 but not GNA12 5,6,9-11 , we found frequent GNA13 coding mutations in GCB-DLBCL and BL biopsy samples, with a number of biallelic cases (Supplementary Table 2 and Extended Data Fig. 2 ). Mixed BM chimera analysis revealed that Gα13-deficiency was sufficient to confer a GC B cell growth advantage in mLNs and to a lesser extent in PPs ( Fig. 1g and Extended Data Fig. 4b ). Gα13-deficient mLN GC B cells showed increased pAkt relative to WT when incubated ex vivo with CXCL12 and S1P (Fig.  1h) . Deficiency in the Gα13 effector, Arhgef1 (p115 RhoGEF or Lsc), led to a similar defect in the ability of S1P to repress chemokine induced pAkt (Fig. 1i ).
To determine whether loss of Gα13 in B cells could promote lymphomagenesis, we allowed a cohort of Gna13-deficient mice to age. At one year, 10 of 18 Gna13-deficient mice showed a greater than 10-fold expansion of GC B cells compared to littermate controls (Fig. 1j, k) and at least five of the outgrowths appeared clonal (Extended Data Fig. 4c) . Three of the Gna13-deficient animals showed massive mesenteric lymphadenopathy ( Fig. 1l and not shown), with evidence in one case (#307) of spleen and PP involvement ( Fig. 1l and Extended Data Fig. 4c-e) . Immunophenotyping of the Gα13-deficient tumors confirmed they were of GC origin (Extended Data Fig. 4f ).
To test the conservation of the Gα13-signaling pathway in human GC B cells, we performed gene rescue experiments in GCB-DLBCL cell lines. Sequencing of S1PR2, GNA13 and ARHGEF1 in a panel of GCB-DLBCL cell lines identified several with deleterious mutations in these genes (Supplementary Table 3 and Extended Data Fig. 5a ). The mutations in GNA13 matched those previously described and were associated with reduced protein levels 6 . ARHGEF1 mutations have not previously been reported, likely because the large size (∼24 kb) of this 27 exon gene and its multiple splice variants and low transcript abundance make sequence analysis difficult. Remarkably, 10 of 20 cell lines with analyzable ARHGEF1 sequence showed mutations in this gene, several of which resulted in premature stop codons (Supplementary Table 3 and Extended Data Fig. 5a ). Using retroviral transduction to restore gene expression, we established that loss of S1PR2, Gα13 and ARHGEF1 were each sufficient to disrupt S1P-mediated suppression of pAKT and, in the case of cell lines that were migratory, to disrupt S1P-mediated inhibition of migration (See Supplementary Text and Extended Data Fig. 5 ).
The mechanisms by which malignant GC B cells can exit the GC niche and lymphoid organ to spread amongst multiple LNs or to systemic sites such as BM have not been defined. Consistent with a lack of migration inhibition by S1P (Fig. 2a) , mice lacking Gα13 in B cells showed marked disruption of GC architecture in mLNs ( Fig. 2b and Extended Data Fig. 6a ). In a mixed transfer system, Gα13-deficient GC B cells were excluded from the interior of otherwise wild-type GCs (Extended Data Fig. 6b) . Remarkably, Gα13-deficient GC B cells were readily detected in lymph and to a lesser extent in blood while WT GC B cells were absent from circulation (Fig. 2c) . In mixed BM chimeras, Gα13-deficient GC B cells were again detectable in the lymph, indicating that Gα13 was needed intrinsically in GC B cells to inhibit egress (Fig. 2d) . Analysis of Arhgef1-deficient mice and chimeras revealed a similar disruption of mLN GC architecture ( Fig. 2b and Extended Data Fig. 6c ) and GC B cell appearance in lymph and blood (Fig. 2e, f) . In contrast, S1PR2-deficient GC B cells were not significantly higher in lymph relative to littermate controls (Fig. 2g) . Analysis of mice expressing constitutively active myr-Akt or over-expressing BCL2 in B cells established that increased GC B cell survival was not sufficient to lead to dissemination (Supplementary Text and Extended Data Fig. 7 ).
GNA13 mutations and BCL2 rearrangements and potentially activating mutations frequently occur together in GCB-DLBCL 6, 12 . GC B cells in mice with combined Gα13-deficiency and BCL2 overexpression showed enhanced ex vivo survival (Fig. 3a) , increased numbers ( Fig.  3b) , wider dispersal throughout the follicle and interfollicular regions in mLNs (Extended Data Fig. 7f ) and 2-fold increased frequencies in lymph and blood (compare Fig. 3c and 2c ), compared to cells in Gα13-deficient mice To examine requirements for GC B cell persistence after arriving at a distant site we bypassed the egress step and intravenously transferred mLN cells to congenically distinct recipients. Transferred WT GC B cells were essentially undetectable in recipient spleen and BM after six hours (Fig. 3d, e) and Gα13-deficiency alone was insufficient to cause a significant increase in their number (Fig. 3e) . Bcl2-overexpression alone caused an elevation in GC B cell frequency in recipient spleens but not BM (Fig. 3e) . Loss of Gα13 combined with Bcl2-overexpression led to greater accumulation of transferred GC B cells in spleen and now led to an increase in their frequency in BM (Fig. 3e) . This combinatorial effect likely reflects an ability of Gα13-deficiency and BCL2-overexpression to cooperate in promoting survival of GC B cells outside the GC niche (Fig. 3a) . To determine whether GC B cells could seed distant LNs after entry into lymphatics, we transferred mLN cells intraperitoneally. Small numbers of Gα13-deficient, but not WT, GC B cells were detectable in the draining parathymic LNs after six hours (Fig. 3f) . In this case, recovery of Gα13-deficient GC B cells was not enhanced by the BCL2 transgene. BM involvement occurs in a fraction of GCB-DLBCL patients and is a predictor of worse disease 13 . In some year old Gα13-deficient mice showing mLN tumors, GC B cells could be detected in the BM (Fig.  3g, h ). Moreover, in aged BCL2-tg Gna13 KO but not BCL2-tg Gna13 WT mice, GC B cells were frequently found in the BM (Fig. 3i) .
The more frequent mutations of GNA13 than of S1PR2 in both GCB-DLBCL and BL despite the similar size of their open reading frames, together with our finding of Gna13-deficient but not S1pr2-deficient mouse GC B cells in circulation ( Fig. 2c and g ) led us to hypothesize that additional Gα13 coupled GPCRs may be involved in GC B cell regulation. In this regard, P2YR8, a gene situated in the pseudoautosomal region of the X chromosome, was a target of mutations in published whole exome sequencing data of GCB-DLBCL and BL 5, 7, 14 and was frequently mutated in our GCB-DLBCL and BL samples, with several of each lymphoma type carrying biallelic mutations (Fig. 4a, Supplementary Table 2 and Extended Data Fig. 2 ). P2RY8 is an orphan receptor and has orthologs in many vertebrates, but unexpectedly it lacks an ortholog in mouse (Fig. 4b) . Like S1PR2, P2RY8 was abundant in human GC B cells (Fig. 4c) . Five out of six tested mutations prevented surface P2RY8 expression (Extended Data Fig. 8a, b) .
Despite the lack of a mouse P2RY8 ortholog, we considered the possibility that if the ligand were a small molecule it may be conserved and we therefore asked whether P2RY8 overexpression influenced GC B cell growth. Remarkably, human P2RY8 led to a suppressive effect on GC B cell growth in mouse PPs and mLNs, similar to the effect of S1PR2 overexpression (Fig. 4d and Extended Data Fig. 8c ). This suppression required P2RY8 coupling to Gα13 as it was not seen if the cells lacked Gna13 (Fig. 4e and Extended Data Fig. 8d ). In short-term transfers, P2RY8-transduced B cells localized in the center of the follicle immediately around and often within GCs while vector transduced cells were dispersed throughout the follicle ( In the absence of Gα13, P2RY8 was unable to direct B cells to the follicle center ( Fig. 4g and Extended Data Fig. 8g ). Importantly, a control Gα13 coupled GPCR, Tbxa2r, could not suppress GC B cell growth or confine cells to the GC niche (Extended Data Fig. 9 and Supplementary Text). These observations lead us to suggest that P2RY8 in humans acts to suppress GC B cell growth and promote B cell positioning in a GC location via Gα13-dependent pathways.
GC B cells are normally tightly regulated in their growth and strictly confined to the GC, and they lack the ability to exit into circulation or to survive outside the GC niche. Each of these processes breaks down in the GC B cell-derived malignancies, GCB-DLBCL and BL. We provide evidence that disruption of Gα13 signaling, via mutations in GNA13, ARHGEF1, S1PR2 or P2RY8, contributes to this breakdown. GNA13 is mutated in 15-33% of GCB-DLBCL and ∼15% of BL 6, 7, [9] [10] [11] (Supplementary Table 2 and Extended Data Fig.  2 ). This is similar to the frequency of mutations in the histone methyltransferases EZH2 and MLL2, deletions of PTEN and amplifications of miR17-92, genetic alterations that have been highlighted for their role in oncogenesis in GCB-DLBCL [15] [16] [17] [18] [19] [20] [21] . Our data support a model (Extended Data Fig. 10 and Supplemental text) where deleterious mutations in Gα13 and its effector, ARHGEF1, are sufficient to deregulate AKT signaling and to cause loss of confinement, allowing egress of GC B cells into circulation; survival of the disseminating cells at distant sites such as BM depends on cooperating mutations affecting additional genes, such as BCL2 12, 22 . S1PR2 and P2RY8 mutations are also suggested to deregulate AKT signaling and growth but may lead to less dissemination due to overlapping roles in promoting confinement. Potentially inactivating mutations of RHOA, a direct target of ARHGEF1 23 , have been reported in BL 24 . The mechanism by which RHOA inhibits AKT activation is not yet defined but might involve activation of PTEN or inhibition of RAC [25] [26] [27] . We suggest that small molecules that inhibit AKT may replace the missing repressive effects of RHO on growth or survival in cells that harbor defects in the S1PR2/ P2RY8-GNA13-ARHGEF1-RHO pathway. Development of active RHO-mimetics may represent a novel therapeutic approach that addresses both lymphoma cell survival and disease dissemination.
Methods

Human samples and Sequencing
All clinical samples were studied with informed consent according to an IRB protocol approved by the National Cancer Institute. Genomic DNA for the single exon coding region of S1PR2 and cDNA for GNA13 or ARHGEF1 was PCR amplified. PCR products were bidirectionally sequenced using an ABI 3730 Genetic Analyzer (Applied Biosystems). Sequence electropherograms were manually reviewed. ARHGEF1 encodes multiple splice variants with up to 28 coding exons per splice variant. We were unable to sequence the open reading frame of ARHGEF1 from cDNA in some cell lines in our panel likely due to splice variation or insufficient transcript. In some cell lines, regions containing coding exons for ARHGEF1 were amplified from genomic DNA. Primers used for amplification and sequencing are shown in Supplementary Table 4 . The following NCBI (RefSeq) accession numbers: ARHGEF1: NM_004706 and NP_004697, GNA13: NM_006572 and NP_006563, S1PR2: NM_004230 and NP_004221 were used to report mutations.
Mice and BM chimeras
Adult C57BL6 Ly5.2 (CD45.1 + ) mice at least 7 weeks of age were from the National Cancer Institute. S1pr2−/− mice 28 were backcrossed for at least six generations to C57BL6/J (B6/J). Arhgef1−/− mice 29 were backcrossed to B6/J for at least 6 generations. Gna13 f/f mice were on a mixed background 30 . Mb1-cre mice (provided by M. Reth) express Cre in all B-lineage cells 31 . BCL2-tg mice were of the EμBcl2-22 line 32 that overexpresses BCL2 selectively in B cells. MD4 Ig-tg mice were from an internal colony. Mice lacking Gna13 in B cells and littermate controls were generated by crossing mb1-cre + Gna13 f/+ mice to Gna13 f/f. In most experiments, bred mice of both sexes were used and were between 7 and 12 weeks of age except in the aging cohort of Gna13 animals as indicated. BM chimeras were made using Ly5.2 (CD45.1 + ) from NCI as hosts as previously described 33 and analyzed at least 8 weeks after reconstitution. For one experiment using S1pr2 heterozygous and WT littermate donors, mice were also heterozygous for beta-2-microglobulin. CD21-cre (Cr2-cre) mice that express Cre in mature B cells were from Jackson Laboratories. The mouse genotype was not blinded from the investigator and mice were not randomized. Mice were housed in a specific pathogen-free environment in the Laboratory Animal Research Center at the University of California, San Francisco, and all animal procedures were approved by the Institutional Animal Care and Use Committee.
Retroviral constructs and transductions
S1PR2, P2RY8, GNA13, ARHGEF1 retroviral constructs were made by inserting the human open reading frame into the MSCV2.2 retroviral vector followed by an internal ribosome entry site (IRES) and Thy1.1 or GFP as an expression marker. The mouse Tbxa2r open reading frame was inserted into the Thy1.1 MSCV2.2 retroviral vector. S1PR2, P2RY8
and Tbxa2r were inserted in frame with a preprolactin leader and FLAG-epitope encoding sequence. Lymphoma-associated mutations were introduced into S1PR2 or P2RY8 by quick-change PCR. WEHI231 or human lymphoma cell lines engineered to express an ecotropic retroviral receptor 34 were spin-infected with retrovirus containing vector, WT or mutant S1PR2, P2RY8, Tbxa2r, GNA13 or ARHGEF1. For transduction of BM, S1pr2 heterozygous or deficient, CD21-cre or Gna13 f/f mb1-cre donor mice were injected IV with 3 mg 5-fluorouracil (Sigma). BM was collected after 4 d and was cultured in DMEM containing 15% (vol/vol) FBS, antibiotics (penicillin(50 IU/ml) and streptomycin (50 μg/ ml); Cellgro) and 10 mM HEPES, pH 7.2 (Cellgro), supplemented with IL-3, IL-6 and stem cell factor (at concentrations of 20, 50 or 100 ng/ml, respectively; Peprotech). Cells were 'spin-infected' twice at days 1 and 2 and were transferred into irradiated recipients on day 3. BM chimeras in which constitutively active myristoylated Akt (myr-Akt) is selectively expressed in B cells were generated by transducing CD21-cre BM with retrovirus in which myr-Akt is downstream of a loxP-stop-loxP cassette 3 . To generate activated B cells that can be efficiently retrovirally transduced, MD4 Ig-transgenic mice (MGI 2384500) containing lysozyme-specific B cells were injected with 5 mg hen egg lysozyme (HEL), splenocytes were harvested 4 hours later and the B cells further activated by culturing with 20 μg/ml anti-CD40 (FGK4.5; BioXcell) for 24 hours as in past studies 35 . Alternatively, Gpr183+/-or Gna13 WT or KO spleen cells were harvested in media containing 1 μg/ml LPS or 0.25 μg/ml anti-CD180 (RP-105; clone RP14, BD Biosciences) and cultured for 24 hours. Later experiments were performed using anti-CD180 activation as we found it much more effective in achieving high levels of transduction than LPS. The activated B cells were spininfected for 2 hours with retroviral supernatant, and cultured overnight before transfer into SRBC-immunized wild-type mice. Transferred cells were analyzed after 24 hours by flow cytometry and immunohistochemistry.
Cell isolation, clonality assessment, adoptive transfer, cell culture, treatments, flow cytometry and qPCR B cells from spleen, mesenteric lymph nodes (mLNs), Peyer's patches (PPs) and blood were isolated and stained as previously described 3 . Lymph was collected from the cysterna chyli via fine glass micropipette as previously described 36 . Assessment of clonality by PCR of J558 heavy chain, and κ and λ light chains from genomic DNA from bulk mLN cells from year old mice was performed as previously described 37 . For adoptive transfer experiments, mLN were harvested, washed once and transferred IV or IP into CD45.1 recipient mice. Spleen and BM were harvested 6 h after IV transfer, parathymic LNs were harvested 6 h after IP transfer. Harvested organs were analyzed by FACS for the presence of donor GC B cells. For GC B cell positioning experiments in a mixed setting, Gna13 WT or KO CD45.2 + B cells were transferred with WT CD45.1 + B cells into MD4 Ig-tg CD45.1 + recipients. Recipients were then immunized with SRBCs and analyzed after 8 days. For pAkt analysis of mLN GC B cells, mLN were harvested in RPM-I1640 medium containing 0.5% (wt/vol) fatty acid-free BSA (migration media; EMD Biosciences). Cells were RBC lysed twice and resuspended in migration media. Cells were incubated for 10 minutes at 37°C and then stimulated for 10 min with CXCL12 (300 ng/ml) or S1P (10 nM). Cells were fixed at a final concentration of 1.5% PFA for 10 min at room temperature and then permeabilized in icecold methanol. Cells were washed twice in staining buffer, blocked with Fc-block (2.4G2; Bio×cell) and 5% normal goat serum for 20 minutes at room temp, stained for 45 min at room temp for Akt phosphorylated at Ser473 (D9E, #4060; Cell Signaling Technology) followed by goat antibody to rabbit IgG conjugated to allophycocyanin (sc-3846; Santa Cruz Biotechnology) as well as antibodies to GC markers. For pAkt analysis by flow cytometry in transduced WEHI231 or human GCB-DLBCL lines, cells were stimulated for five minutes with or without CXCL12 (100 ng/ml) with or without S1P (1 nM for WEHI-231 or 10 nM for human GCB-DLBCL lines) and fixed and stained as above for pAkt as well as antiThy1.1 conjugated to phycoerythrin (clone ox-7; Biolegend). Human cell lines used in this manuscript were tested for mycoplasma contamination. Mycoplasma positive lines were treated with MycoZap (Lonza) and Plasmocin (InvivoGen). All human cell lines were tested for a unique profile of polymorphic DNA copy number variants (CNV fingerprint; unpublished protocol from L. Bergsagel). In some experiments, cells were treated with the PI3K inhibitors wortmannin (Sigma) or GS-1101 (Selleck Chemicals) as negative pAkt staining controls. For active caspase-3 staining, total mLN cells were harvested, washed once and incubated in RPMI-I1640 containing 10% FCS for 3h at 37, cells were stained for surface markers, fixed and permeabilized with BD Cytofix/Cytoperm and stained with antiactive Caspase-3 conjugated to biotin (clone: C92-605; BD Biosciences) according to manufacturer's instructions. Chemotaxis assays of GC B cells were performed using total mLN cells that were RBC lysed twice or transduced WEHI231 or human GCB-DLBCL lines as described 3 . U-46619 was from Cayman Chemicals. Flow cytometry was performed on a FACSCalibur or LSRii (BD Biosciences). For qPCR analysis of gene expression in GC B cells, Ptprc (encoding CD45) was used as a control since its expression was unchanged between Fo and GC B cells by microarray (Immgen.org and unpublished data), RNAseq analysis (unpublished) and by surface staining. In contrast, Gapdh and Hprt were both upregulated in GC B cells (Immgen.org and unpublished data).
Western Blotting
WEHI231 cells transduced with vector, WT or mutant human S1PR2 were washed twice in migration media and incubated at 37°C for 30 minutes, washed once in cold PBS and lysed in 0.5% Brij 35, 0.5% NP40, 150mM NaCl, 10mM Tris-HCl, pH 7.4 with protease inhibitor cocktail (Roche) for 1 hour on ice. Lysate were centrifuged and supernatant were mixed with loading buffer and reducing agent and incubated at room temp for 30 min. Samples were resolved by SDS-PAGE and FLAG expression was detected with rabbit polyclonal anti-FLAG (Sigma). For pAkt western blot experiments Ly7, Ly8 or WEHI cells that were sorted based on Thy1.1 expression and expanded were stimulated as above and lysed in 2× sample buffer and resolved by SDS-PAGE and probed with rabbit anti-pAkt S473 (D9E, #4060; Cell Signaling Technology).
Immunohistochemical analysis
Cryosections 7 μm in thickness from mLN and spleen were cut and prepared as described 3 . Tumor immunopheotyping was performed using goat polyclonal IRF4 antibody (Santa Cruz, sc-6059) or biotinylated anti-mouse CD138 (clone 281-2; BD Biosciences). For Bcl-6 staining, cryosections were fixed with 4% PFA for 10 minutes and stained with rabbit polyclonal Bcl6 antibody (Santa Cruz, sc-368). Images were captured with a Zeiss AxioOberver Z1 inverted microscope.
Statistical analysis
Prism software (GraphPad) was used for all statistical analysis. Data were analyzed with a two-sample unpaired (or paired, where indicated) Student's t-test. P values were considered significant when ≤ 0.05. The hydrogen bond network tightens the interactions between transmembrane helices TM3 and TM4. We hypothesize that this network stabilizes the putative active state conformation of S1PR2. Such a network is broken in the R147C mutant and hence this mutant does not activate the G-protein. splenic nodule from #307 (see Fig. 1l ) for GC marker GL7 (blue) and naïve B cell marker IgD (brown). Scale bar is 500 μm. (f) Control or enlarged Gna13 KO mLNs were stained for the GC B cell markers GL7 and Bcl6, the plasma cell markers CD138 and IRF4, and the follicular B cell marker IgD. Scale bar is 200 μm in all samples in f.
Extended Data
Extended Data Figure 5 . Defective regulation of pAkt and cell migration in human GCB DLBCL cell lines harboring mutations in the S1PR2 signaling pathway (a) Frequency of non-synonymous coding mutations in S1PR2, GNA13 and ARHGEF1 in GCB-DLBCL lines, and fraction that were mono-or bi-allelic, summarized from Supplementary Table 3 
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